Sign In
Buy NWBO
$0.191
-0.0008 (-0.417%)
At Close: Jun 22, 2026
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
12:30pm, Thursday, 30'th Apr 2026
BETHESDA, Md., April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for sol
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
09:30am, Tuesday, 21'st Apr 2026
BETHESDA, Md., April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for soli
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?
04:09am, Wednesday, 01'st Apr 2026
Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.25 and traded
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)
03:31am, Sunday, 18'th Jan 2026
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both medical companies, but which is the better investment? We will compare the two compa
Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Passes Below 200-Day Moving Average – Here’s Why
03:44am, Saturday, 22'nd Nov 2025
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) shares passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.2
BETHESDA, Md. , Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tum
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
12:03pm, Friday, 24'th Oct 2025
BETHESDA, Md. , Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for soli
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
12:39pm, Wednesday, 27'th Aug 2025
BETHESDA, Md. , Aug. 27, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for soli
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
12:37pm, Monday, 18'th Aug 2025
BETHESDA, Md. , Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tum
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
12:49pm, Wednesday, 11'th Jun 2025
BETHESDA, Md. , June 11, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tu
BETHESDA, Md. , Dec. 26, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tum
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
11:56am, Wednesday, 03'rd Jul 2024
Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company de
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
09:30am, Monday, 17'th Jun 2024
Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, Md. , June 17, 2024 /PRNewswire/ -- Northwest Biotherapeutics (
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
11:09am, Thursday, 21'st Mar 2024
BETHESDA, Md. , March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, ann
Accompanied by Broad Patent Coverage BETHESDA, Md. , Feb. 6, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune the
